Rebecca Kamerer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebecca Kamerer has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Timothy M. Fan
Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois
149 shared publications - Allison Sheen
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
120 shared publications - Elizabeth Fink
Department of Chemical Engineering, Massachusetts Institute of Technology; Cambridge, MA, USA
120 shared publications - Jordan A. Stinson
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
120 shared publications - Jordan Hampel
Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois. 3
120 shared publications - Karl Dane Wittrup
Department of Chemical Engineering Massachusetts Institute of Technology Cambridge Massachusetts USA
120 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Dose/Tumor Volume ratio and correlation with best response.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Dose/Tumor Volume ratio and correlation with best response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Characterization of anti-drug antibody (ADA) responses in dogs at day 63 (dose 4).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Characterization of anti-drug antibody (ADA) responses in dogs at day 63 (dose 4).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Summary of anti-drug antibody titers at indicated timepoint by ELISA.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Summary of anti-drug antibody titers at indicated timepoint by ELISA.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplemental Data File containing raw data generated in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplemental Data File containing raw data generated in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Best response observed in treated evaluable patients by investigator assessment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Best response observed in treated evaluable patients by investigator assessment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Incidence of JEN-101 adverse events in 2 or more dogs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Incidence of JEN-101 adverse events in 2 or more dogs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Safety hematological and biochemical profile of JEN-101 treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Safety hematological and biochemical profile of JEN-101 treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Patient 006 treated with JEN-101 and a CTLA-4 inhibitor.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Patient 006 treated with JEN-101 and a CTLA-4 inhibitor.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
NanoString RNA cell type profiling and pathway scores of primary tumor lesions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
NanoString RNA cell type profiling and pathway scores of primary tumor lesions.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Pharmacokinetic parameters of JEN-101.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Pharmacokinetic parameters of JEN-101.